

Hisataka Yasuda

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8861835/publications.pdf>

Version: 2024-02-01

15
papers

3,223
citations

759055

12
h-index

940416

16
g-index

16
all docs

16
docs citations

16
times ranked

2563
citing authors

#	ARTICLE	IF	CITATIONS
1	Induction of chondrogenesis with a RANKL-binding peptide, WP9QY, in vitro and in vivo in a rabbit model. <i>Biochemical and Biophysical Research Communications</i> , 2022, 602, 98-104.	1.0	2
2	Discovery of the RANKL/RANK/OPG system. <i>Journal of Bone and Mineral Metabolism</i> , 2021, 39, 2-11.	1.3	83
3	The W9 peptide directly stimulates osteoblast differentiation via RANKL signaling. <i>Journal of Oral Biosciences</i> , 2017, 59, 146-151.	0.8	6
4	Treatment of OPG-deficient mice with WP9QY, a RANKL-binding peptide, recovers alveolar bone loss by suppressing osteoclastogenesis and enhancing osteoblastogenesis. <i>PLoS ONE</i> , 2017, 12, e0184904.	1.1	31
5	Peptide drugs accelerate BMP2-induced calvarial bone regeneration and stimulate osteoblast differentiation through mTORC1 signaling. <i>BioEssays</i> , 2016, 38, 717-725.	1.2	25
6	The local administration of TNF- α and RANKL antagonist peptide promotes BMP-2-induced bone formation. <i>Journal of Oral Biosciences</i> , 2013, 55, 47-54.	0.8	19
7	Stimulation of Bone Formation in Cortical Bone of Mice Treated with a Receptor Activator of Nuclear Factor- κ B Ligand (RANKL)-binding Peptide That Possesses Osteoclastogenesis Inhibitory Activity. <i>Journal of Biological Chemistry</i> , 2013, 288, 5562-5571.	1.6	65
8	Establishment of a new murine model of hypercalcemia with anorexia by overexpression of soluble receptor activator of NF- κ B ligand using an adenovirus vector. <i>Journal of Bone and Mineral Metabolism</i> , 2011, 29, 414-421.	1.3	13
9	Increased Bone Mass in Mice after Single Injection of Anti-receptor Activator of Nuclear Factor- κ B Ligand-neutralizing Antibody. <i>Journal of Biological Chemistry</i> , 2011, 286, 37023-37031.	1.6	55
10	Evaluation of Pharmaceuticals With a Novel 50-Hour Animal Model of Bone Loss. <i>Journal of Bone and Mineral Research</i> , 2009, 24, 1194-1205.	3.1	103
11	Transgenic mice overexpressing soluble osteoclast differentiation factor (sODF) exhibit severe osteoporosis. <i>Journal of Bone and Mineral Metabolism</i> , 2002, 20, 337-344.	1.3	133
12	Severe Osteoporosis in Mice Lacking Osteoclastogenesis Inhibitory Factor/Osteoprotegerin. <i>Biochemical and Biophysical Research Communications</i> , 1998, 247, 610-615.	1.0	724
13	RANK Is the Essential Signaling Receptor for Osteoclast Differentiation Factor in Osteoclastogenesis. <i>Biochemical and Biophysical Research Communications</i> , 1998, 253, 395-400.	1.0	660
14	Identity of Osteoclastogenesis Inhibitory Factor (OCIF) and Osteoprotegerin (OPG): A Mechanism by which OPG/OCIF Inhibits Osteoclastogenesis <i>in Vitro</i> . <i>Endocrinology</i> , 1998, 139, 1329-1337.	1.4	1,095
15	Identity of a tumor cytotoxic factor from human fibroblasts and hepatocyte growth factor. <i>Biochemical and Biophysical Research Communications</i> , 1990, 170, 397-404.	1.0	208